跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 13 天前AI 评分59

Charming Medical未申请听证,纳斯达克证券交易将于11月9日开市时暂停

6-K - Charming Medical Ltd (0002035992) (Filer)

AI 导读

Charming Medical Limited披露,公司未在11月5日截止日期前申请听证,因此其证券将在11月9日开市时暂停在纳斯达克交易。纳斯达克随后将向SEC提交Form 25-NSE,以将公司证券从纳斯达克上市及注册中移除。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-42907

CHARMING MEDICAL LIMITED

(Translation of registrant’s name into English)

Units 1803-1806, 18/F, Hang Lung Centre, 2-20 Paterson Street, Causeway Bay, Hong Kong

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒           Form 40-F ☐

Nasdaq Delisting Determination and Suspension of Trading

As previously disclosed, Charming Medical Limited (the “Company”) received a delisting determination letter, dated October 29, 2026, from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq had determined to delist the Company’s securities pursuant to Nasdaq Listing Rule IM-5101-4.

The Company did not request a hearing by the November 5, 2026 deadline. As a result, trading in the Company’s securities on Nasdaq will be suspended at the opening of business on November 9, 2026. Nasdaq will subsequently file a Form 25-NSE with the U.S. Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market.

The Company issued a press release on November 9, 2026, announcing the upcoming suspension of trading in the Company’s securities on Nasdaq. A copy of this press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Forward-Looking Statements

This Form 6-K contains forward-looking statements that involve risks and uncertainties. The risks and uncertainties involved include market conditions and other risks detailed from time to time in the Company’s periodic reports and other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company’s current expectations and assumptions and speak only as of the date of this Form 6-K. The Company does not intend to revise or update any forward-looking statement in this Form 6-K as a result of new information, future events or otherwise, except as required by law.

Financial Statements and Exhibits

The following exhibit is being furnished herewith:

Exhibit No.   Description
99.1   Press Release Dated November 9, 2026

1 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 9, 2026

  Charming Medical Limited
     
  By: /s/ Kit Wong
  Name:  Kit Wong
  Title: Chief Executive Officer and
Chairman of the Board of Directors

2 

来源:SEC EDGAR · 本站存档